TR200001557T2 - Oksa-ikameli bileşikler, yapım işlemi ve parp etkinliğinin engellenmesi için bileşimler ve yöntemler. - Google Patents

Oksa-ikameli bileşikler, yapım işlemi ve parp etkinliğinin engellenmesi için bileşimler ve yöntemler.

Info

Publication number
TR200001557T2
TR200001557T2 TR2000/01557T TR200001557T TR200001557T2 TR 200001557 T2 TR200001557 T2 TR 200001557T2 TR 2000/01557 T TR2000/01557 T TR 2000/01557T TR 200001557 T TR200001557 T TR 200001557T TR 200001557 T2 TR200001557 T2 TR 200001557T2
Authority
TR
Turkey
Prior art keywords
compounds
ring
methods
making
independently hydrogen
Prior art date
Application number
TR2000/01557T
Other languages
English (en)
Inventor
Li Jia-He
L. Tays Kevin
Zhang Jie
Original Assignee
Guilford Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guilford Pharmaceuticals, Inc. filed Critical Guilford Pharmaceuticals, Inc.
Publication of TR200001557T2 publication Critical patent/TR200001557T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C07D221/12—Phenanthridines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/93—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

En azindan bir halka azotunu ihtiva eden (I) formülünün bilesiklerinin ya da bir farmasötik açidan kabul edilebilir bazi ya da asit ilave tuzu, hidrat,ester, solvant, ön-ilaç, metabolit, stereoizomer ya da karisimlarinin yapilmasi için islemler, bilesiklerin kullanilmasi için yöntemler ve bilesikleri ihtiva eden bilesimler olup, (I) formülünde, X, bir iki-bagli oksijen ya da-oh'dir; R7 mevcutsa, hidrojen ya da alt alkildir; y, bir kaynasik tek-iki-ya da üç-siklik, karbosiklik ya da heterosiklik halkayi olusturmak için gerekli atomlari temsil etmektedir, her tek halka 5-6 halka elemani atomuna sahiptir; ve Z, (I)-CH2CHR3-dür, burada, R2 ve R3 bagimsiz olarak hidrojen alkil, aril ya da aralkildir; (II)-R6C=CR-dür, burada,R3 veR6 bagimsiz olarak hidrojen, alt alkil, aralkil, halo, -NO2,COOR7 yada-NR7R8'dir, burada, R8 bagimsiz olarak hidrojen ya da C1-C9 alkildir, ya da R6 ve R3 birlikte alindiginda bir kaynasik aromatik halka olusturmaktadir (DEVAMI VAR).
TR2000/01557T 1997-09-03 1998-09-02 Oksa-ikameli bileşikler, yapım işlemi ve parp etkinliğinin engellenmesi için bileşimler ve yöntemler. TR200001557T2 (tr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92252097A 1997-09-03 1997-09-03
US7950998A 1998-05-15 1998-05-15
US09/145,180 US20020022636A1 (en) 1997-09-03 1998-09-01 Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity

Publications (1)

Publication Number Publication Date
TR200001557T2 true TR200001557T2 (tr) 2001-01-22

Family

ID=27373494

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/01557T TR200001557T2 (tr) 1997-09-03 1998-09-02 Oksa-ikameli bileşikler, yapım işlemi ve parp etkinliğinin engellenmesi için bileşimler ve yöntemler.

Country Status (14)

Country Link
US (2) US20020022636A1 (tr)
EP (1) EP1009739A2 (tr)
JP (1) JP2002512637A (tr)
KR (1) KR20010023909A (tr)
CN (1) CN1278797A (tr)
AU (1) AU9298698A (tr)
BR (1) BR9812428A (tr)
CA (1) CA2294118A1 (tr)
HU (1) HUP0004693A3 (tr)
IL (1) IL134847A0 (tr)
NO (1) NO20001002L (tr)
PL (1) PL339082A1 (tr)
TR (1) TR200001557T2 (tr)
WO (1) WO1999011624A1 (tr)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291425B1 (en) * 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
EP1077944A1 (en) * 1998-05-15 2001-02-28 Guilford Pharmaceuticals Inc. Carboxamide compounds, compositions, and methods for inhibiting parp activity
PT1140936E (pt) 1999-01-11 2004-06-30 Agouron Pharma Inibidores triciclicos de poli(adp-ribose) polimerases
AU3076700A (en) 1999-01-26 2000-08-18 Ono Pharmaceutical Co. Ltd. 2h-phthalazin-1-one derivatives and drugs comprising these derivatives as the active ingredient
JP2001002572A (ja) * 1999-04-19 2001-01-09 Sankyo Co Ltd ニューロトロフィン作用増強剤
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
US6531464B1 (en) * 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
US6476048B1 (en) 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
US6277990B1 (en) 1999-12-07 2001-08-21 Inotek Corporation Substituted phenanthridinones and methods of use thereof
US6534651B2 (en) * 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
US7122679B2 (en) 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
US6723733B2 (en) * 2000-05-19 2004-04-20 Guilford Pharmaceuticals, Inc. Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses
EP1325918A4 (en) * 2000-08-31 2004-03-10 Takeda Chemical Industries Ltd CARDIOUS CELL APOPTOSIS INHIBITORS AND TREATMENT / PREVENTION OF HEART DISEASES
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
AU3652102A (en) 2000-12-01 2002-06-11 Guilford Pharm Inc Compounds and their uses
WO2002045702A2 (en) * 2000-12-05 2002-06-13 Chemokine Therapeutics Corporation Tricyclic therapeutics for chemokine mediated diseases
CA2330350A1 (en) 2000-12-05 2002-06-05 Chemokine Therapeutics Corporation Therapeutics for chemokine mediated diseases
AUPR201600A0 (en) * 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
ATE355278T1 (de) 2001-05-08 2006-03-15 Kudos Pharm Ltd Isochinolinon derivate als parp inhibitoren
AUPS019702A0 (en) * 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
AUPS137402A0 (en) * 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
CA2482806A1 (en) 2002-04-30 2003-11-13 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US7425563B2 (en) * 2002-07-24 2008-09-16 Kyorin Pharmaceutical Co., Ltd. 4-(Substituted aryl)-5-hydroxyisoquinolinone derivative
JP4520406B2 (ja) 2002-10-01 2010-08-04 田辺三菱製薬株式会社 イソキノリン化合物及びその医薬用途
EP2325225B2 (en) 2002-10-30 2019-12-11 Sumitomo Chemical Company, Limited Complex aryl copolymer compounds and polymer light emitting devices made by using the same
ES2376166T3 (es) 2002-11-22 2012-03-09 Mitsubishi Tanabe Pharma Corporation Compuestos de isoquinolina y su uso medicinal.
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
HU227948B1 (en) 2003-04-30 2012-07-30 Pecsi Tudomanyegyetem Quinazoline derivatives and their use for the preparation of pharmaceutical compositions inhibiting parp enzyme
US20050008699A1 (en) * 2003-07-11 2005-01-13 Fred Wehling Effervescent glucosamine composition
CA2546300C (en) 2003-11-20 2012-10-02 Janssen Pharmaceutica N.V. 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
JP4806353B2 (ja) * 2003-12-05 2011-11-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ポリ（ａｄｐ−リボース）ポリメラーゼインヒビターとしての６−置換２−キノリノンおよび２−キノキサリノン
TW200536830A (en) 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
DE102004028973A1 (de) 2004-06-16 2006-01-05 Sanofi-Aventis Deutschland Gmbh Substituierte Tetrahydro-2H-isochinolin-1-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
TWI389897B (zh) 2005-02-22 2013-03-21 Chugai Pharmaceutical Co Ltd 1- (2H) -isoquinolinone derivatives
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
CA2629376C (en) 2005-11-14 2015-06-09 Centre National De La Recherche Scientifique - Cnrs Inhibitors of parp activity and uses thereof
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
PT2061765E (pt) * 2006-09-01 2015-02-06 Senhwa Biosciences Inc Moduladores de serina-treonina-proteína-quinase e de parp
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
JP5496680B2 (ja) * 2006-12-28 2014-05-21 アッヴィ・インコーポレイテッド ポリ（ａｄｐ−リボース）ポリメラーゼの阻害剤
CN101641013B (zh) * 2007-01-22 2014-07-30 Gtx公司 核受体结合剂
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
DK2118074T3 (en) 2007-02-01 2014-03-10 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular diseases
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
WO2008107478A1 (en) 2007-03-08 2008-09-12 Janssen Pharmaceutica Nv Quinolinone derivatives as parp and tank inhibitors
WO2008141081A1 (en) * 2007-05-10 2008-11-20 Amr Technology, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
MX2010002749A (es) 2007-09-14 2010-06-25 Astrazeneca Ab Derivados de ftalazinona.
EP2205565B1 (en) * 2007-09-14 2013-04-17 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones
NZ584145A (en) 2007-09-14 2012-03-30 Ortho Mcneil Janssen Pharm 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1,4'] bipyridinyl-2'-ones
EA019085B1 (ru) 2007-09-14 2014-01-30 Янссен Фармасьютикалз, Инк. 1',3-двузамещенные 4-(арил-х-фенил)-1н-пиридин-2-оны
JP5525447B2 (ja) * 2007-10-26 2014-06-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐａｒｐ阻害剤としてのキノリノン誘導体
MX2010005110A (es) * 2007-11-14 2010-09-09 Ortho Mcneil Janssen Pharm Derivados de imidazo[1,2-a]piridina y su uso como moduladores alostericos positivos de los receptores de glutamato metabotropico 2.
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
ES2439291T3 (es) 2008-09-02 2014-01-22 Janssen Pharmaceuticals, Inc. Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
EA020783B1 (ru) 2008-10-07 2015-01-30 Астразенека Юк Лимитед Фармацевтическая композиция, содержащая 4-[3-(4-циклопропанкарбонилпиперазин-1-карбонил)-4-фторбензил]-2н-фталазин-1-он и коповидон
EP2355660A4 (en) * 2008-10-13 2012-05-02 Biovista Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
US8697689B2 (en) 2008-10-16 2014-04-15 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
US8815891B2 (en) * 2008-11-11 2014-08-26 Je Il Pharmaceutical Co., Ltd. Tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same
EP2377871A4 (en) 2008-11-28 2012-07-25 Chugai Pharmaceutical Co Ltd 1- (2H) -ISOCHINOLONDERIVAT
MX2011005242A (es) 2008-11-28 2011-09-06 Ortho Mcneil Janssen Pharm Derivados de indol y benzoxazina como moduladores de los receptores de glutamato metabotropicos.
CA2992231C (en) 2009-03-18 2022-03-29 Resverlogix Corp. Phenyl-quinazolin-4(3h)-one and phenyl-pyrido[2,3-d]pyrimidin-4(3h)-one derivatives and compositions thereof useful as anti-inflammatory agents
MY161325A (en) 2009-05-12 2017-04-14 Janssen Pharmaceuticals Inc 1, 2, 4-triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
CA2760259C (en) 2009-05-12 2018-05-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
JP5852664B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
CN103298809B (zh) 2010-11-08 2016-08-31 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
CN103814032A (zh) 2011-07-13 2014-05-21 诺华股份有限公司 用作端锚聚合酶抑制剂的4-氧代-3,5,7,8-四氢-4H-吡喃并[4,3-d]嘧啶基化合物
KR20140051944A (ko) 2011-07-13 2014-05-02 노파르티스 아게 탄키라제 억제제로서 사용하기 위한 4-피페리디닐 화합물
US9181266B2 (en) 2011-07-13 2015-11-10 Novartis Ag 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
WO2015110435A1 (en) 2014-01-21 2015-07-30 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
KR102662814B1 (ko) 2015-03-13 2024-05-03 리스버로직스 코퍼레이션 보체 관련 질환을 치료하기 위한 조성물 및 치료 방법
EP3263104A1 (en) * 2016-07-01 2018-01-03 N-Gene Research Laboratories Inc. Use of bgp15 to stimulate mitochondrial fusion
WO2018022851A1 (en) 2016-07-28 2018-02-01 Mitobridge, Inc. Methods of treating acute kidney injury
CN106798745A (zh) * 2016-08-31 2017-06-06 四川省人民医院 一种用于治疗肿瘤疾病的药物
WO2018085359A1 (en) 2016-11-02 2018-05-11 Immunogen, Inc. Combination treatment with antibody-drug conjugates and parp inhibitors
CN109293584B (zh) * 2018-09-25 2021-11-26 暨南大学 靶向神经肽受体pac1-r的小分子别构调节化合物spam及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1880441A (en) * 1932-10-04 Etjbole m
US3291801A (en) * 1963-05-23 1966-12-13 Grace W R & Co Novel octahydro-6(5)-phenanthridinones and preparation thereof
DE2355084A1 (de) * 1972-11-06 1974-05-16 Guidotti & C Spa Labor Verbindungen mit magensaeuresekretionshemmender wirkung und verfahren zu deren herstellung
US3932643A (en) * 1974-01-07 1976-01-13 Pfizer Inc. Phenanthridines and phenanthridinones as antiviral agents
SU514825A1 (ru) * 1974-02-04 1976-05-25 Химико-Фармацевтический Завод "Фармакон" Способ получени хлоргидрата 1-фенил1-циклогексил-3-(1,-пиперидино) -пропанола-1
GB9404485D0 (en) * 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
US5589483A (en) * 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence

Also Published As

Publication number Publication date
HUP0004693A3 (en) 2001-12-28
PL339082A1 (en) 2000-12-04
HUP0004693A2 (hu) 2001-10-28
WO1999011624A1 (en) 1999-03-11
BR9812428A (pt) 2000-09-26
NO20001002L (no) 2000-04-27
KR20010023909A (ko) 2001-03-26
WO1999011624B1 (en) 1999-04-22
CN1278797A (zh) 2001-01-03
AU9298698A (en) 1999-03-22
EP1009739A2 (en) 2000-06-21
JP2002512637A (ja) 2002-04-23
US20030105102A1 (en) 2003-06-05
CA2294118A1 (en) 1999-03-11
NO20001002D0 (no) 2000-02-28
US20020022636A1 (en) 2002-02-21
IL134847A0 (en) 2001-05-20

Similar Documents

Publication Publication Date Title
TR200001557T2 (tr) Oksa-ikameli bileşikler, yapım işlemi ve parp etkinliğinin engellenmesi için bileşimler ve yöntemler.
PT1023308E (pt) Inibidores do metabolismo nucleosidico
HUP0400694A2 (hu) A rotamáz enzim aktivitásának kis molekulájú inhibitorai, valamint ezeket a vegyületeket tartalmazó gyógyászati készítmények
HK1080856A1 (en) Compounds having selective inhibiting effect at gsk3
NO20024217D0 (no) 1,5-benzotiazepiner og deres anvendelse som hypolipidmidler
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
AR008377A1 (es) Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto
ATE67503T1 (de) 17-beta-substituierte-4-aza-5-alpha-androstenon und ihre anwendung als 5-alpha-reduktaseinhibitoren.
MX9302300A (es) Derivados esteroides para el tratamiento de hipertrofia prostatica, su preparacion y sus usos.
NZ227436A (en) Cell proliferation inhibiting composition comprising a substituted styrene derivative
IL104090A0 (en) Phosphonosuccinic acid derivatives,processes for the preparation thereof and pharmaceutical compositions containing these compounds
ATE428696T1 (de) Nitroxyderivate mit entzündungshemmender, analgetischer und antithrombotischer wirkung
BG104853A (en) Thienylazolylalcoxyethanamines, their preparation and their application as medicaments
HUT46313A (en) Process for producing 3/2h/-pyridazine derivatives and pharmaceutical compositions containing them as active components
DK164915C (da) Anvendelse af 17beta-methoxycarbonyl-4-aza-4-methyl-5alfa-androst-1-en-3-on til fremstilling af et topisk praeparat
ES2081747B1 (es) Amidas derivadas de tienopirroles, su preparacion y su aplicacion como medicamentos.
CO4990933A1 (es) Derivados de indazol triciclicos, su preparacion y su apli- cacion en terapeutica
DK26289D0 (da) Anvendelse af 1,4-disubstitueret piperidinyl til fremstilling af et farmaceutisk praeparat til behandling af insomnia
MY129176A (en) Tetrahydro gamma-carbolines
HUP0400545A2 (hu) Uro-szelektív alfa1-adrenoceptor gátlóanyagokként használatos 1,4-diszubsztituált piperazinszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
ES8608476A1 (es) Procedimiento de preparacion de nuevos derivados a-etilben- zol con un grupo dialquilaminoalcoxi sustituido y de sus sa-les de adicion acidas y amonicas cuaternarias
AP1518A (en) Novel octahydro-6, 10-dioxo-6h-pyridazino/1,2-a/ /1,2/diazepin-1-carboxylic acid derivatives, preparation method and use for preparing therapeutically active compounds.
MA20369A1 (fr) Compositions a base de derives de la piperidine ,nouveaux derives de la piperidine et leurs procedes de preparation
NZ505110A (en) Neuroprotective agents
HUP0000080A2 (hu) Metallopeptidáz inhibitor hatású foszfonsav-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények